Rare Disease or Orphan Drug Treatment Denied by Insurance? Here's How to Appeal

Living with a rare disease is difficult enough without fighting your insurance company for access to treatments your physician has determined are necessary. Yet insurance denials for rare disease therapies — including FDA-approved orphan drugs, enzyme replacement therapies, gene therapies, and compassionate use treatments — are among the most common and most devastating claim denials in American healthcare. Rare diseases affect approximately 30 million Americans, and nearly 95% have no FDA-approved treatment. For those who do have approved therapies, insurance barriers are a daily reality. If your rare disease treatment has been denied, you have legal rights, clinical arguments, and a meaningful path to appeal.

Why Insurers Deny Rare Disease Treatments

Rare disease treatment denials follow several recurring patterns that you should anticipate and address directly in your appeal.

"Experimental or investigational" designations. Even FDA-approved orphan drugs are sometimes labeled experimental by insurers, particularly for drugs that are newer or prescribed for a disease subtype slightly outside the precise approved indication. FDA approval for an orphan drug under the Orphan Drug Act (21 U.S.C. § 360aa et seq.) is legally dispositive against any claim that the drug is experimental for its approved use. Your appeal should cite this directly.

Off-label use denials. Because rare disease patient populations are small, FDA-approved clinical trials may not encompass every patient subset. Many patients receive treatments approved for closely related conditions. Insurers deny these uses despite strong scientific rationale, specialist consensus, and published compendia support. For off-label uses, cite the NCCN Drugs & Biologics Compendium, DrugDex, or Clinical Pharmacology — these compendia are recognized coverage references under most insurance policies.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denials without adequate clinical review. Rare diseases often require specialist expertise that insurer medical reviewers — typically general practitioners or hospitalists — do not possess. Their reviews may be clinically uninformed. Request that the insurer assign a reviewer with relevant specialty expertise, or that your specialist conduct a peer-to-peer review.

Step therapy ("fail first") requirements. Insurers mandate trials of cheaper or more common therapies before approving the recommended rare disease treatment. For many rare diseases, no clinical evidence supports the mandated step therapy alternative, and the requirement violates the principles of evidence-based medicine. Many states now have step therapy override laws requiring exceptions for rare diseases and conditions where the alternative therapy is contraindicated.

High-cost pharmacy benefit exclusions. Gene therapies and enzyme replacement therapies can cost hundreds of thousands of dollars annually. Insurers apply extraordinary scrutiny to these claims and sometimes place them in specialty pharmacy tiers with prohibitive cost-sharing.

How to Appeal a Rare Disease Denial

Step 1: Identify the Precise Denial Reason and the ICD-10 Code

Obtain your denial letter and EOB. Identify the exact reason code and the clinical criteria cited. Verify that your diagnosis is documented with the correct ICD-10 code — for example, Gaucher disease is E75.22, Fabry disease is E75.21, and phenylketonuria (PKU) is E70.0. Coding accuracy is essential because many coverage policies are triggered by specific diagnosis codes.

Step 2: Request the Insurer's Clinical Coverage Policy

Most insurers maintain published clinical coverage policies (also called coverage determination policies or CDPs) for specific treatments. Request the exact policy document the insurer applied to your claim. Compare it against the FDA label, NORD (National Organization for Rare Disorders) treatment guidelines, and published specialist society guidelines. Coverage policies that conflict with the FDA-approved indication or established rare disease guidelines are legally and clinically contestable.

Step 3: Obtain a Detailed Letter from Your Rare Disease Specialist

Your appeal must be anchored by a comprehensive letter from the specialist managing your care — typically a clinical geneticist, metabolic disease specialist, rheumatologist, or other relevant sub-specialist. The letter should state your diagnosis with ICD-10 code, explain the clinical rationale for the specific treatment requested, cite published clinical guidelines or peer-reviewed literature supporting the treatment, address why alternative treatments are not appropriate or contraindicated, and describe the clinical consequences of continued denial.

Step 4: Contact the Drug Manufacturer's Patient Assistance Program

Most orphan drug manufacturers — including Sanofi Genzyme, BioMarin, Ultragenyx, Alexion, and others — have dedicated patient assistance and reimbursement support programs. These teams have experience appealing insurer denials, can provide coverage support letters, and may supply the medication at no cost while your appeal is pending. Contact them simultaneously with your appeal.

Step 5: Request External Independent Review

After exhausting internal appeals, request independent external review. Under the ACA, most health plans must offer external review for medical necessity denials. External reviewers with rare disease expertise are significantly more likely to understand the clinical necessity of FDA-approved orphan drug treatments. Expedited external review — available within 72 hours for urgent situations — is appropriate if delay poses a health risk.

Step 6: Contact Your State Insurance Commissioner and NORD

File a complaint with your state insurance commissioner. Also contact NORD (rarediseases.org), which has a Rare Disease Patient Assistance Program and can connect you with advocacy organizations that specialize in insurance access for specific rare diseases. NORD maintains disease-specific resources and can provide supporting documentation for your appeal.

What to Include in Your Appeal

• Denial letter and EOB with specific denial reason, ICD-10 diagnosis code, and clinical criteria cited
• Insurer's clinical coverage policy compared against FDA labeling, NORD guidelines, and published specialist guidelines
• Detailed letter from your rare disease specialist addressing each denial reason with clinical citations
• Published peer-reviewed literature or compendia supporting the treatment for your specific condition
• Documentation from the drug manufacturer's medical affairs or patient support team confirming FDA-approved indication or compendia listing for off-label use

Fight Back With ClaimBack

Rare disease treatment denials based on "experimental" or "not medically necessary" designations are frequently overturned when the correct clinical and legal arguments are presented. FDA-approved orphan drugs treating their approved indication have both a strong clinical case and a strong legal case for coverage. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal